Global Dalbavancin Market

Dalbavancin Comprehensive Study by Type (Intravenous Therapy, Oral Type), Application (Skin Infection, Soft Tissue Infection, Others), End Users (Hospitals and clinics, Chemical firms, API demanding firms, Pharmacy Retailers/Distributor/Stockist, Clinical trials), Treatment (Acute Bacterial Skin, Skin Structure Infections, Osteomyelitis, Others) Players and Region - Global Market Outlook to 2028

Dalbavancin Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Market Overview:
Dalbavancin is also known for following names such as xydalba and Dalvance. Dalbavancin is second-generation antibiotic lipoglycopeptide highly used for skin-related disorders and diseases. It is available in oral and IV route of administration. Only disadvantage is it is high cost associated product.It is the one best treatment used for skin diseases and disorders.It basically acts on gram negative bacteria .Dalbavancin is the major API demanded by various firms for different dosage production and research purpose also.



AttributesDetails
Study Period2018-2028
Base Year2022
Forecast Period2023-2028
Historical Period2018-2022
UnitValue (USD Million)
Key Companies ProfiledTeva api (Durata Therapeutics) (Israel), Allergan plc (Ireland), LGM pharma (United States), Manus aktteva (India), Tecoland(United States), Sigma-Aldrich (Merck KGaA) (Germany), Fuzhou Contay Biotechnology Co., Ltd(China), BrightGene Bio-Medical Technology Co., Ltd (China) and Selleck Chem(United States)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region or narrow down segments in the final scope subject to feasibility


AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics of major and emerging geographies across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Key Players of Dalbavancin Market Study:
Teva api (Durata Therapeutics) (Israel), Allergan plc (Ireland), LGM pharma (United States), Manus aktteva (India), Tecoland(United States), Sigma-Aldrich (Merck KGaA) (Germany), Fuzhou Contay Biotechnology Co., Ltd(China), BrightGene Bio-Medical Technology Co., Ltd (China) and Selleck Chem(United States)

Dalbavancin Market Segment Analysis
ScopeSub-Segments
Application / End UserSkin Infection, Soft Tissue Infection and Others
TypeIntravenous Therapy and Oral Type
End UsersHospitals and clinics,Chemical firms,API demanding firms,Pharmacy Retailers/Distributor/Stockist,Clinical trials
TreatmentAcute Bacterial Skin,Skin Structure Infections,Osteomyelitis,Others


Influencing Trend:
IV Route Administration Widely Used Over Oral Dosage

Market Growth Drivers:
Growing No Of Skin Infection Patients

Challenges:
High Cost Associated With Drug

Restraints:
Mild Side Effects Such As Headache, Nausea, Diarrhoea

Opportunities:
Emerging New Skin Disorders And Infections

.

Latest Industry Highlights:
January, 2022, Paladin Labs Inc., a subsidiary of Endo International plc ,has launched of Xydalba® (dalbavancin for injection), a 30-minute intravenous (IV) therapy for acute bacterial skin and skin structure infections (ABSSSI) that can be administered as a single- or two-dose regimen.
Actavis (Teva api) acquired Durata Therapeutics, Inc. which help to enhance the growth of the company., and In March 2020, ADVANZ PHARMA Corp. Limited a global pharmaceutical company had acquired pharmaceutical company Correvio Pharma Corp.


Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Dalbavancin market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Dalbavancin market.
Identification of total players or companies operating in the global market which is further concentrated to fewer or most impacting players which are considered under the report’s scope. In order to make a priority list sorting is done based on revenue generated based on the latest reporting with the help of paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Manufacturers, Hospital and diagnostic Centres, Distributors/Suppliers/Wholesalers, Government sector, Research firms, Industry Associate and Downstream Vendors.

This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Intravenous Therapy
  • Oral Type
By Application
  • Skin Infection
  • Soft Tissue Infection
  • Others
By End Users
  • Hospitals and clinics
  • Chemical firms
  • API demanding firms
  • Pharmacy Retailers/Distributor/Stockist
  • Clinical trials

By Treatment
  • Acute Bacterial Skin
  • Skin Structure Infections
  • Osteomyelitis
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Growing No Of Skin Infection Patients
    • 3.3. Market Challenges
      • 3.3.1. High Cost Associated With Drug
    • 3.4. Market Trends
      • 3.4.1. IV Route Administration Widely Used Over Oral Dosage
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Dalbavancin, by Type, Application, End Users, Treatment and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Dalbavancin (Value)
      • 5.2.1. Global Dalbavancin by: Type (Value)
        • 5.2.1.1. Intravenous Therapy
        • 5.2.1.2. Oral Type
      • 5.2.2. Global Dalbavancin by: Application (Value)
        • 5.2.2.1. Skin Infection
        • 5.2.2.2. Soft Tissue Infection
        • 5.2.2.3. Others
      • 5.2.3. Global Dalbavancin by: End Users (Value)
        • 5.2.3.1. Hospitals and clinics
        • 5.2.3.2. Chemical firms
        • 5.2.3.3. API demanding firms
        • 5.2.3.4. Pharmacy Retailers/Distributor/Stockist
        • 5.2.3.5. Clinical trials
      • 5.2.4. Global Dalbavancin by: Treatment (Value)
        • 5.2.4.1. Acute Bacterial Skin
        • 5.2.4.2. Skin Structure Infections
        • 5.2.4.3. Osteomyelitis
        • 5.2.4.4. Others
      • 5.2.5. Global Dalbavancin Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Dalbavancin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teva api (Durata Therapeutics) (Israel)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Allergan plc (Ireland)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. LGM pharma (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Manus aktteva (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Tecoland(United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Sigma-Aldrich (Merck KGaA) (Germany)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Fuzhou Contay Biotechnology Co., Ltd(China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. BrightGene Bio-Medical Technology Co., Ltd (China)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Selleck Chem(United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
  • 7. Global Dalbavancin Sale, by Type, Application, End Users, Treatment and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Dalbavancin (Value)
      • 7.2.1. Global Dalbavancin by: Type (Value)
        • 7.2.1.1. Intravenous Therapy
        • 7.2.1.2. Oral Type
      • 7.2.2. Global Dalbavancin by: Application (Value)
        • 7.2.2.1. Skin Infection
        • 7.2.2.2. Soft Tissue Infection
        • 7.2.2.3. Others
      • 7.2.3. Global Dalbavancin by: End Users (Value)
        • 7.2.3.1. Hospitals and clinics
        • 7.2.3.2. Chemical firms
        • 7.2.3.3. API demanding firms
        • 7.2.3.4. Pharmacy Retailers/Distributor/Stockist
        • 7.2.3.5. Clinical trials
      • 7.2.4. Global Dalbavancin by: Treatment (Value)
        • 7.2.4.1. Acute Bacterial Skin
        • 7.2.4.2. Skin Structure Infections
        • 7.2.4.3. Osteomyelitis
        • 7.2.4.4. Others
      • 7.2.5. Global Dalbavancin Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Dalbavancin: by Type(USD Million)
  • Table 2. Dalbavancin Intravenous Therapy , by Region USD Million (2017-2022)
  • Table 3. Dalbavancin Oral Type , by Region USD Million (2017-2022)
  • Table 4. Dalbavancin: by Application(USD Million)
  • Table 5. Dalbavancin Skin Infection , by Region USD Million (2017-2022)
  • Table 6. Dalbavancin Soft Tissue Infection , by Region USD Million (2017-2022)
  • Table 7. Dalbavancin Others , by Region USD Million (2017-2022)
  • Table 8. Dalbavancin: by End Users(USD Million)
  • Table 9. Dalbavancin Hospitals and clinics , by Region USD Million (2017-2022)
  • Table 10. Dalbavancin Chemical firms , by Region USD Million (2017-2022)
  • Table 11. Dalbavancin API demanding firms , by Region USD Million (2017-2022)
  • Table 12. Dalbavancin Pharmacy Retailers/Distributor/Stockist , by Region USD Million (2017-2022)
  • Table 13. Dalbavancin Clinical trials , by Region USD Million (2017-2022)
  • Table 14. Dalbavancin: by Treatment(USD Million)
  • Table 15. Dalbavancin Acute Bacterial Skin , by Region USD Million (2017-2022)
  • Table 16. Dalbavancin Skin Structure Infections , by Region USD Million (2017-2022)
  • Table 17. Dalbavancin Osteomyelitis , by Region USD Million (2017-2022)
  • Table 18. Dalbavancin Others , by Region USD Million (2017-2022)
  • Table 19. South America Dalbavancin, by Country USD Million (2017-2022)
  • Table 20. South America Dalbavancin, by Type USD Million (2017-2022)
  • Table 21. South America Dalbavancin, by Application USD Million (2017-2022)
  • Table 22. South America Dalbavancin, by End Users USD Million (2017-2022)
  • Table 23. South America Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 24. Brazil Dalbavancin, by Type USD Million (2017-2022)
  • Table 25. Brazil Dalbavancin, by Application USD Million (2017-2022)
  • Table 26. Brazil Dalbavancin, by End Users USD Million (2017-2022)
  • Table 27. Brazil Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 28. Argentina Dalbavancin, by Type USD Million (2017-2022)
  • Table 29. Argentina Dalbavancin, by Application USD Million (2017-2022)
  • Table 30. Argentina Dalbavancin, by End Users USD Million (2017-2022)
  • Table 31. Argentina Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 32. Rest of South America Dalbavancin, by Type USD Million (2017-2022)
  • Table 33. Rest of South America Dalbavancin, by Application USD Million (2017-2022)
  • Table 34. Rest of South America Dalbavancin, by End Users USD Million (2017-2022)
  • Table 35. Rest of South America Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 36. Asia Pacific Dalbavancin, by Country USD Million (2017-2022)
  • Table 37. Asia Pacific Dalbavancin, by Type USD Million (2017-2022)
  • Table 38. Asia Pacific Dalbavancin, by Application USD Million (2017-2022)
  • Table 39. Asia Pacific Dalbavancin, by End Users USD Million (2017-2022)
  • Table 40. Asia Pacific Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 41. China Dalbavancin, by Type USD Million (2017-2022)
  • Table 42. China Dalbavancin, by Application USD Million (2017-2022)
  • Table 43. China Dalbavancin, by End Users USD Million (2017-2022)
  • Table 44. China Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 45. Japan Dalbavancin, by Type USD Million (2017-2022)
  • Table 46. Japan Dalbavancin, by Application USD Million (2017-2022)
  • Table 47. Japan Dalbavancin, by End Users USD Million (2017-2022)
  • Table 48. Japan Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 49. India Dalbavancin, by Type USD Million (2017-2022)
  • Table 50. India Dalbavancin, by Application USD Million (2017-2022)
  • Table 51. India Dalbavancin, by End Users USD Million (2017-2022)
  • Table 52. India Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 53. South Korea Dalbavancin, by Type USD Million (2017-2022)
  • Table 54. South Korea Dalbavancin, by Application USD Million (2017-2022)
  • Table 55. South Korea Dalbavancin, by End Users USD Million (2017-2022)
  • Table 56. South Korea Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 57. Taiwan Dalbavancin, by Type USD Million (2017-2022)
  • Table 58. Taiwan Dalbavancin, by Application USD Million (2017-2022)
  • Table 59. Taiwan Dalbavancin, by End Users USD Million (2017-2022)
  • Table 60. Taiwan Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 61. Australia Dalbavancin, by Type USD Million (2017-2022)
  • Table 62. Australia Dalbavancin, by Application USD Million (2017-2022)
  • Table 63. Australia Dalbavancin, by End Users USD Million (2017-2022)
  • Table 64. Australia Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 65. Rest of Asia-Pacific Dalbavancin, by Type USD Million (2017-2022)
  • Table 66. Rest of Asia-Pacific Dalbavancin, by Application USD Million (2017-2022)
  • Table 67. Rest of Asia-Pacific Dalbavancin, by End Users USD Million (2017-2022)
  • Table 68. Rest of Asia-Pacific Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 69. Europe Dalbavancin, by Country USD Million (2017-2022)
  • Table 70. Europe Dalbavancin, by Type USD Million (2017-2022)
  • Table 71. Europe Dalbavancin, by Application USD Million (2017-2022)
  • Table 72. Europe Dalbavancin, by End Users USD Million (2017-2022)
  • Table 73. Europe Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 74. Germany Dalbavancin, by Type USD Million (2017-2022)
  • Table 75. Germany Dalbavancin, by Application USD Million (2017-2022)
  • Table 76. Germany Dalbavancin, by End Users USD Million (2017-2022)
  • Table 77. Germany Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 78. France Dalbavancin, by Type USD Million (2017-2022)
  • Table 79. France Dalbavancin, by Application USD Million (2017-2022)
  • Table 80. France Dalbavancin, by End Users USD Million (2017-2022)
  • Table 81. France Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 82. Italy Dalbavancin, by Type USD Million (2017-2022)
  • Table 83. Italy Dalbavancin, by Application USD Million (2017-2022)
  • Table 84. Italy Dalbavancin, by End Users USD Million (2017-2022)
  • Table 85. Italy Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 86. United Kingdom Dalbavancin, by Type USD Million (2017-2022)
  • Table 87. United Kingdom Dalbavancin, by Application USD Million (2017-2022)
  • Table 88. United Kingdom Dalbavancin, by End Users USD Million (2017-2022)
  • Table 89. United Kingdom Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 90. Netherlands Dalbavancin, by Type USD Million (2017-2022)
  • Table 91. Netherlands Dalbavancin, by Application USD Million (2017-2022)
  • Table 92. Netherlands Dalbavancin, by End Users USD Million (2017-2022)
  • Table 93. Netherlands Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 94. Rest of Europe Dalbavancin, by Type USD Million (2017-2022)
  • Table 95. Rest of Europe Dalbavancin, by Application USD Million (2017-2022)
  • Table 96. Rest of Europe Dalbavancin, by End Users USD Million (2017-2022)
  • Table 97. Rest of Europe Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 98. MEA Dalbavancin, by Country USD Million (2017-2022)
  • Table 99. MEA Dalbavancin, by Type USD Million (2017-2022)
  • Table 100. MEA Dalbavancin, by Application USD Million (2017-2022)
  • Table 101. MEA Dalbavancin, by End Users USD Million (2017-2022)
  • Table 102. MEA Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 103. Middle East Dalbavancin, by Type USD Million (2017-2022)
  • Table 104. Middle East Dalbavancin, by Application USD Million (2017-2022)
  • Table 105. Middle East Dalbavancin, by End Users USD Million (2017-2022)
  • Table 106. Middle East Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 107. Africa Dalbavancin, by Type USD Million (2017-2022)
  • Table 108. Africa Dalbavancin, by Application USD Million (2017-2022)
  • Table 109. Africa Dalbavancin, by End Users USD Million (2017-2022)
  • Table 110. Africa Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 111. North America Dalbavancin, by Country USD Million (2017-2022)
  • Table 112. North America Dalbavancin, by Type USD Million (2017-2022)
  • Table 113. North America Dalbavancin, by Application USD Million (2017-2022)
  • Table 114. North America Dalbavancin, by End Users USD Million (2017-2022)
  • Table 115. North America Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 116. United States Dalbavancin, by Type USD Million (2017-2022)
  • Table 117. United States Dalbavancin, by Application USD Million (2017-2022)
  • Table 118. United States Dalbavancin, by End Users USD Million (2017-2022)
  • Table 119. United States Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 120. Canada Dalbavancin, by Type USD Million (2017-2022)
  • Table 121. Canada Dalbavancin, by Application USD Million (2017-2022)
  • Table 122. Canada Dalbavancin, by End Users USD Million (2017-2022)
  • Table 123. Canada Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 124. Mexico Dalbavancin, by Type USD Million (2017-2022)
  • Table 125. Mexico Dalbavancin, by Application USD Million (2017-2022)
  • Table 126. Mexico Dalbavancin, by End Users USD Million (2017-2022)
  • Table 127. Mexico Dalbavancin, by Treatment USD Million (2017-2022)
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Dalbavancin: by Type(USD Million)
  • Table 138. Dalbavancin Intravenous Therapy , by Region USD Million (2023-2028)
  • Table 139. Dalbavancin Oral Type , by Region USD Million (2023-2028)
  • Table 140. Dalbavancin: by Application(USD Million)
  • Table 141. Dalbavancin Skin Infection , by Region USD Million (2023-2028)
  • Table 142. Dalbavancin Soft Tissue Infection , by Region USD Million (2023-2028)
  • Table 143. Dalbavancin Others , by Region USD Million (2023-2028)
  • Table 144. Dalbavancin: by End Users(USD Million)
  • Table 145. Dalbavancin Hospitals and clinics , by Region USD Million (2023-2028)
  • Table 146. Dalbavancin Chemical firms , by Region USD Million (2023-2028)
  • Table 147. Dalbavancin API demanding firms , by Region USD Million (2023-2028)
  • Table 148. Dalbavancin Pharmacy Retailers/Distributor/Stockist , by Region USD Million (2023-2028)
  • Table 149. Dalbavancin Clinical trials , by Region USD Million (2023-2028)
  • Table 150. Dalbavancin: by Treatment(USD Million)
  • Table 151. Dalbavancin Acute Bacterial Skin , by Region USD Million (2023-2028)
  • Table 152. Dalbavancin Skin Structure Infections , by Region USD Million (2023-2028)
  • Table 153. Dalbavancin Osteomyelitis , by Region USD Million (2023-2028)
  • Table 154. Dalbavancin Others , by Region USD Million (2023-2028)
  • Table 155. South America Dalbavancin, by Country USD Million (2023-2028)
  • Table 156. South America Dalbavancin, by Type USD Million (2023-2028)
  • Table 157. South America Dalbavancin, by Application USD Million (2023-2028)
  • Table 158. South America Dalbavancin, by End Users USD Million (2023-2028)
  • Table 159. South America Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 160. Brazil Dalbavancin, by Type USD Million (2023-2028)
  • Table 161. Brazil Dalbavancin, by Application USD Million (2023-2028)
  • Table 162. Brazil Dalbavancin, by End Users USD Million (2023-2028)
  • Table 163. Brazil Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 164. Argentina Dalbavancin, by Type USD Million (2023-2028)
  • Table 165. Argentina Dalbavancin, by Application USD Million (2023-2028)
  • Table 166. Argentina Dalbavancin, by End Users USD Million (2023-2028)
  • Table 167. Argentina Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 168. Rest of South America Dalbavancin, by Type USD Million (2023-2028)
  • Table 169. Rest of South America Dalbavancin, by Application USD Million (2023-2028)
  • Table 170. Rest of South America Dalbavancin, by End Users USD Million (2023-2028)
  • Table 171. Rest of South America Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 172. Asia Pacific Dalbavancin, by Country USD Million (2023-2028)
  • Table 173. Asia Pacific Dalbavancin, by Type USD Million (2023-2028)
  • Table 174. Asia Pacific Dalbavancin, by Application USD Million (2023-2028)
  • Table 175. Asia Pacific Dalbavancin, by End Users USD Million (2023-2028)
  • Table 176. Asia Pacific Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 177. China Dalbavancin, by Type USD Million (2023-2028)
  • Table 178. China Dalbavancin, by Application USD Million (2023-2028)
  • Table 179. China Dalbavancin, by End Users USD Million (2023-2028)
  • Table 180. China Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 181. Japan Dalbavancin, by Type USD Million (2023-2028)
  • Table 182. Japan Dalbavancin, by Application USD Million (2023-2028)
  • Table 183. Japan Dalbavancin, by End Users USD Million (2023-2028)
  • Table 184. Japan Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 185. India Dalbavancin, by Type USD Million (2023-2028)
  • Table 186. India Dalbavancin, by Application USD Million (2023-2028)
  • Table 187. India Dalbavancin, by End Users USD Million (2023-2028)
  • Table 188. India Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 189. South Korea Dalbavancin, by Type USD Million (2023-2028)
  • Table 190. South Korea Dalbavancin, by Application USD Million (2023-2028)
  • Table 191. South Korea Dalbavancin, by End Users USD Million (2023-2028)
  • Table 192. South Korea Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 193. Taiwan Dalbavancin, by Type USD Million (2023-2028)
  • Table 194. Taiwan Dalbavancin, by Application USD Million (2023-2028)
  • Table 195. Taiwan Dalbavancin, by End Users USD Million (2023-2028)
  • Table 196. Taiwan Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 197. Australia Dalbavancin, by Type USD Million (2023-2028)
  • Table 198. Australia Dalbavancin, by Application USD Million (2023-2028)
  • Table 199. Australia Dalbavancin, by End Users USD Million (2023-2028)
  • Table 200. Australia Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 201. Rest of Asia-Pacific Dalbavancin, by Type USD Million (2023-2028)
  • Table 202. Rest of Asia-Pacific Dalbavancin, by Application USD Million (2023-2028)
  • Table 203. Rest of Asia-Pacific Dalbavancin, by End Users USD Million (2023-2028)
  • Table 204. Rest of Asia-Pacific Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 205. Europe Dalbavancin, by Country USD Million (2023-2028)
  • Table 206. Europe Dalbavancin, by Type USD Million (2023-2028)
  • Table 207. Europe Dalbavancin, by Application USD Million (2023-2028)
  • Table 208. Europe Dalbavancin, by End Users USD Million (2023-2028)
  • Table 209. Europe Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 210. Germany Dalbavancin, by Type USD Million (2023-2028)
  • Table 211. Germany Dalbavancin, by Application USD Million (2023-2028)
  • Table 212. Germany Dalbavancin, by End Users USD Million (2023-2028)
  • Table 213. Germany Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 214. France Dalbavancin, by Type USD Million (2023-2028)
  • Table 215. France Dalbavancin, by Application USD Million (2023-2028)
  • Table 216. France Dalbavancin, by End Users USD Million (2023-2028)
  • Table 217. France Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 218. Italy Dalbavancin, by Type USD Million (2023-2028)
  • Table 219. Italy Dalbavancin, by Application USD Million (2023-2028)
  • Table 220. Italy Dalbavancin, by End Users USD Million (2023-2028)
  • Table 221. Italy Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 222. United Kingdom Dalbavancin, by Type USD Million (2023-2028)
  • Table 223. United Kingdom Dalbavancin, by Application USD Million (2023-2028)
  • Table 224. United Kingdom Dalbavancin, by End Users USD Million (2023-2028)
  • Table 225. United Kingdom Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 226. Netherlands Dalbavancin, by Type USD Million (2023-2028)
  • Table 227. Netherlands Dalbavancin, by Application USD Million (2023-2028)
  • Table 228. Netherlands Dalbavancin, by End Users USD Million (2023-2028)
  • Table 229. Netherlands Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 230. Rest of Europe Dalbavancin, by Type USD Million (2023-2028)
  • Table 231. Rest of Europe Dalbavancin, by Application USD Million (2023-2028)
  • Table 232. Rest of Europe Dalbavancin, by End Users USD Million (2023-2028)
  • Table 233. Rest of Europe Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 234. MEA Dalbavancin, by Country USD Million (2023-2028)
  • Table 235. MEA Dalbavancin, by Type USD Million (2023-2028)
  • Table 236. MEA Dalbavancin, by Application USD Million (2023-2028)
  • Table 237. MEA Dalbavancin, by End Users USD Million (2023-2028)
  • Table 238. MEA Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 239. Middle East Dalbavancin, by Type USD Million (2023-2028)
  • Table 240. Middle East Dalbavancin, by Application USD Million (2023-2028)
  • Table 241. Middle East Dalbavancin, by End Users USD Million (2023-2028)
  • Table 242. Middle East Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 243. Africa Dalbavancin, by Type USD Million (2023-2028)
  • Table 244. Africa Dalbavancin, by Application USD Million (2023-2028)
  • Table 245. Africa Dalbavancin, by End Users USD Million (2023-2028)
  • Table 246. Africa Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 247. North America Dalbavancin, by Country USD Million (2023-2028)
  • Table 248. North America Dalbavancin, by Type USD Million (2023-2028)
  • Table 249. North America Dalbavancin, by Application USD Million (2023-2028)
  • Table 250. North America Dalbavancin, by End Users USD Million (2023-2028)
  • Table 251. North America Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 252. United States Dalbavancin, by Type USD Million (2023-2028)
  • Table 253. United States Dalbavancin, by Application USD Million (2023-2028)
  • Table 254. United States Dalbavancin, by End Users USD Million (2023-2028)
  • Table 255. United States Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 256. Canada Dalbavancin, by Type USD Million (2023-2028)
  • Table 257. Canada Dalbavancin, by Application USD Million (2023-2028)
  • Table 258. Canada Dalbavancin, by End Users USD Million (2023-2028)
  • Table 259. Canada Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 260. Mexico Dalbavancin, by Type USD Million (2023-2028)
  • Table 261. Mexico Dalbavancin, by Application USD Million (2023-2028)
  • Table 262. Mexico Dalbavancin, by End Users USD Million (2023-2028)
  • Table 263. Mexico Dalbavancin, by Treatment USD Million (2023-2028)
  • Table 264. Research Programs/Design for This Report
  • Table 265. Key Data Information from Secondary Sources
  • Table 266. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Dalbavancin: by Type USD Million (2017-2022)
  • Figure 5. Global Dalbavancin: by Application USD Million (2017-2022)
  • Figure 6. Global Dalbavancin: by End Users USD Million (2017-2022)
  • Figure 7. Global Dalbavancin: by Treatment USD Million (2017-2022)
  • Figure 8. South America Dalbavancin Share (%), by Country
  • Figure 9. Asia Pacific Dalbavancin Share (%), by Country
  • Figure 10. Europe Dalbavancin Share (%), by Country
  • Figure 11. MEA Dalbavancin Share (%), by Country
  • Figure 12. North America Dalbavancin Share (%), by Country
  • Figure 13. Global Dalbavancin share by Players 2022 (%)
  • Figure 14. Global Dalbavancin share by Players (Top 3) 2022(%)
  • Figure 15. Global Dalbavancin share by Players (Top 5) 2022(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Teva api (Durata Therapeutics) (Israel) Revenue, Net Income and Gross profit
  • Figure 18. Teva api (Durata Therapeutics) (Israel) Revenue: by Geography 2022
  • Figure 19. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 20. Allergan plc (Ireland) Revenue: by Geography 2022
  • Figure 21. LGM pharma (United States) Revenue, Net Income and Gross profit
  • Figure 22. LGM pharma (United States) Revenue: by Geography 2022
  • Figure 23. Manus aktteva (India) Revenue, Net Income and Gross profit
  • Figure 24. Manus aktteva (India) Revenue: by Geography 2022
  • Figure 25. Tecoland(United States) Revenue, Net Income and Gross profit
  • Figure 26. Tecoland(United States) Revenue: by Geography 2022
  • Figure 27. Sigma-Aldrich (Merck KGaA) (Germany) Revenue, Net Income and Gross profit
  • Figure 28. Sigma-Aldrich (Merck KGaA) (Germany) Revenue: by Geography 2022
  • Figure 29. Fuzhou Contay Biotechnology Co., Ltd(China) Revenue, Net Income and Gross profit
  • Figure 30. Fuzhou Contay Biotechnology Co., Ltd(China) Revenue: by Geography 2022
  • Figure 31. BrightGene Bio-Medical Technology Co., Ltd (China) Revenue, Net Income and Gross profit
  • Figure 32. BrightGene Bio-Medical Technology Co., Ltd (China) Revenue: by Geography 2022
  • Figure 33. Selleck Chem(United States) Revenue, Net Income and Gross profit
  • Figure 34. Selleck Chem(United States) Revenue: by Geography 2022
  • Figure 35. Global Dalbavancin: by Type USD Million (2023-2028)
  • Figure 36. Global Dalbavancin: by Application USD Million (2023-2028)
  • Figure 37. Global Dalbavancin: by End Users USD Million (2023-2028)
  • Figure 38. Global Dalbavancin: by Treatment USD Million (2023-2028)
  • Figure 39. South America Dalbavancin Share (%), by Country
  • Figure 40. Asia Pacific Dalbavancin Share (%), by Country
  • Figure 41. Europe Dalbavancin Share (%), by Country
  • Figure 42. MEA Dalbavancin Share (%), by Country
  • Figure 43. North America Dalbavancin Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Teva api (Durata Therapeutics) (Israel)
  • Allergan plc (Ireland)
  • LGM pharma (United States)
  • Manus aktteva (India)
  • Tecoland(United States)
  • Sigma-Aldrich (Merck KGaA) (Germany)
  • Fuzhou Contay Biotechnology Co., Ltd(China)
  • BrightGene Bio-Medical Technology Co., Ltd (China)
  • Selleck Chem(United States)
Select User Access Type

Key Highlights of Report


Nov 2023 227 Pages 53 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Dalbavancin Market Quantitative research analysis
Global Dalbavancin Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

"IV Route Administration Widely Used Over Oral Dosage" is seen as one of major influencing trends for Dalbavancin Market during projected period 2022-2028.
The Concentration Rate of Global Dalbavancin market is highlighted using HHI Index.
Players will contribute the maximum growth of Global Dalbavancin market throughout the predicted period.

Know More About Global Dalbavancin Market Report?

Have a Query? Click Here

Other Related Reports

Pharmaceutical Cold Chain Logistics Comprehensive Study by Application (Pharmaceuticals, CRO, Others), Drug Supply Stage (Outsourced, In-house), Service (Transportation (Type (Sea freight, Airfreight...
$ 3750
Recombinant Human Serum Albumins Comprehensive Study by Type (OsrHSA, ScrHSA), Application (Drug Formulation, Pharmaceuticals, Diagnostics, Coating of Medical Devices, Vitro Fertilization, Cosmetic, ...
$ 3450
Naproxen Comprehensive Study by Type (Tablet, Capsule, Other), Application (Rheumatoid Arthritis, Gout, Other), Distribution Channels (Pharmaceutical Stores, Clinics, Others) Players and Region - Glo...
$ 3500
Erythromycin Comprehensive Study by Form (Gel, Tablet, Topical Solution, Ointment, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Therapeutic Indications (...
$ 3650
Dystonia Drugs Comprehensive Study by Route of Administration (Oral, Injectable), Drug Types (Capsules, Tablets, Other), Dystonias syndromes (Blepharospasm, Cervical dystonia, Cranial dystonia, Tardi...
$ 3750
Vertigo Drugs Comprehensive Study by Route of Administration (Oral, Injection), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy), Class (Anticholinergics, Antihistamines, Be...
$ 3650